Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
NCT07412691Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BG-A3004 in alopecia areata, lichen planus (LP) and nonsegmental vitiligo (NSV) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 36 weeks. Started Mar 2026; status: recruiting.
02
Drugs
BG-A3004
03
Conditions
alopecia areatalichen planus (LP)nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT07412691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412691.